To date, there is no effective therapy for APLAID and treatment with tumor necrosis factor (TNF) inhibitors and the interleukin (IL)-1 receptor antagonist anakinra only partially improved the disease course5. This evidence concerns the gene TNF and autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation.